Actively Recruiting
Culturally Responsive Integrated Harm Reduction Services for Black and Latinx People Who Use Drugs
Led by NYU Langone Health · Updated on 2026-03-19
200
Participants Needed
3
Research Sites
78 weeks
Total Duration
On this page
Sponsors
N
NYU Langone Health
Lead Sponsor
N
National Institute of General Medical Sciences (NIGMS)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating an integrated harm reduction intervention (IHRI) compared to usual harm reduction services for Black and Latinx people who use drugs (PWUD). The study aims to improve the use of harm reduction services among this highly marginalized population. The trial is interventional and focuses on addressing substance abuse and related mental health issues through culturally tailored support. The integrated harm reduction intervention lasts 8 weeks and includes weekly education lessons during the first 4 weeks led by an IHRI care coordinator. During the following 4 weeks, participants receive personalized identification of social vulnerabilities to connect them with relevant social service organizations. Both the IHRI group and the usual harm reduction services group interact with mobile vans providing information on syringe exchange, clean user kits, naloxone use, and fentanyl strip distribution. Participants will be involved for up to 8 weeks, with researchers monitoring their attendance at harm reduction sessions and changes in substance use patterns, overdose risk, and quality of life. Key measurements include the percentage attending harm reduction sessions, changes in days of opioid or stimulant use, overdose risk assessment scores, and quality of life scores. The study includes random assignment to groups and does not involve masking or blinding.
CONDITIONS
Brief Title
Harm Reduction Services
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 18 years of age
- Self-identified as misusing opioids with or without other substances (stimulants) in the past 30 days, confirmed by DSM-5 criteria interview
- English or Spanish speaking
- Able to provide informed consent
You will not qualify if you...
- Unable to provide informed consent or participate in study procedures
- Active suicidal or homicidal thoughts or unstable psychotic or severe mood disorders
- Unwillingness to be randomized
- Currently a prisoner
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 weeks
Participants in the intervention group participate in an 8-week Integrated Harm Reduction Intervention program including weekly education lessons and referrals to social service organizations. Participants in the control group receive usual harm reduction services through mobile vans offering information and supplies.
Weekly visits for up to 8 weeks
Trial Site Locations
Total: 3 locations
1
Yale University
New Haven, Connecticut, United States, 06520
Actively Recruiting
2
NYU Langone Health
New York, New York, United States, 10016
Not Yet Recruiting
3
Nathan Kline Institute
Orangeburg, New York, United States, 10962
Actively Recruiting
Research Team
A
Ayana Jordan, MD, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here